Aventis Pharmaceuticals Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nuvalent Appoints Michael L Meyers, MD, PhD, to Board of Directors

/PRNewswire/ Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically.

New yorkUnited statesMemorial sloan kettering cancer centerUnited kingdomMichaell meyersJames porterNuvalent incPrnewswire nuvalent incMedicine at columbia presbyterian medical centerCompany quarterly report on formUs oncology medical affairsAlbert einstein college of medicineAventis pharmaceuticals incPlough research instituteExchange commissionSyndax pharmaceuticals inc

Nuvalent Inc (NUVL) Appoints Michael L Meyers to its Board

Nuvalent Inc (NUVL) Appoints Michael L Meyers to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMemorial sloan kettering cancer centerMichaell meyersJames porterNuvalent incUs oncology medical affairsAlbert einstein college of medicineAventis pharmaceuticals incPlough research instituteSyndax pharmaceuticals incMedicine at columbia presbyterian medical centerSenior clinical advisorChief executive officerSenior vice presidentChief development officer

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesPoulenc rorerDebra charlesworthMark allesTraci mccartyJean jacques bienaimAntengene corporationCelgene corporationAventis pharmaceuticals incBiomarin pharmaceutical incLock haven university of pennsylvaniaPoint therapeutics incPrnewswire biomarin pharmaceutical incSyros pharmaceuticals incMarin pharmaceuticalChief executive officer

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

/PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment.

United statesPoulenc rorerDebra charlesworthMark allesTraci mccartyJean jacques bienaimAntengene corporationCelgene corporationAventis pharmaceuticals incBiomarin pharmaceutical incLock haven university of pennsylvaniaPoint therapeutics incSyros pharmaceuticals incBiomarin pharmaceuticalChief executive officerBristol myers squibb company

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

/PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment.

United statesPoulenc rorerDebra charlesworthMark allesTraci mccartyJean jacques bienaimAntengene corporationCelgene corporationAventis pharmaceuticals incBiomarin pharmaceutical incLock haven university of pennsylvaniaPoint therapeutics incSyros pharmaceuticals incBiomarin pharmaceuticalChief executive officerBristol myers squibb company